Wilex AG said that a Phase 2 proof-of-concept trial of its cancer therapy, Mesupron combined with capecitabine, was more effective than capecitabine alone in patients with HER2-receptor negative metastatic breast cancer.
Zealand Pharma A/S and its partner, Sanofi SA, have presented further data supporting their candidate treatment for Type 2 diabetes, lixisenatide (Lyxumia). Lixisenatide is a glucagon-like peptide-1 agonist.
Eli Lilly and Company said that a Phase 2b study of baricitinib, a JAK inhibitor being developed for rheumatoid arthritis, reached its primary endpoint by showing a statistically significant response as measured by a scoring system.
Affiris AG has started a Phase 1 study of a new vaccine for Parkinson’s disease which it says is aimed at modifying the disease rather than treating symptoms. The programme has received financial support from the Michael J Fox Foundation.
Addex Therapeutics Ltd said that its partner, Janssen Pharmaceuticals Inc (Johnson & Johnson), is to start a Phase 2 study of an allosteric modulator for major depressive disorder, with anxiety symptoms. The same drug is being studied in schizophrenia.
A Phase 2 trial of gantenerumab, an experimental antibody treatment for early Alzheimer’s disease, is being expanded with a view to preparing for registration, MorphoSys AG announced. The trial is being conducted by Roche.
Immatics Biotechnologies GmbH has reported new data from a Phase 2 study of its experimental vaccine for advanced colorectal cancer which showed that patients survived longer compared with a matched cohort from a larger UK Medical Research Council-supported study (COIN). The data were presented on 1 June at the annual meeting of the American Society of Clinical Oncology in Chicago.